https://www.thebodypro.com/category/symtuza-pro

Cobicistat/Darunavir/Emtricitabine/Tenofovir Alafenamide (Symtuza, D/C/F/TAF)

The Latest

illustration of person on cliff with arms raised as sun rises/sets
News

This Week in HIV Research: From PrEP to Treatment, There's Always More to Learn

April 18, 2019: lamivudine/raltegravir for PrEP; feminizing hormone may impact PrEP efficacy; why TAF has a better renal profile than TDF; the role of internet dating in HIV incidence trends.

Promo Image
News

This Week in HIV Research: Renal Upsides for Tenofovir Alafenamide

E/C/F/TAF viability for dialysis patients; TAF safety following renal damage; mental health needs for American Indians; parenting desires of people with HIV.

FDA Approves First PI-Based Single-Tablet Treatment for HIV -- How Will It Be Used? Img
News

FDA Approves First PI-Based Single-Tablet Treatment for HIV -- How Will It Be Used?

Paul Sax, M.D., says that while most patients prefer the simplicity of having one pill, one prescription, and one co-pay, the new Symtuza (D/C/F/TAF) tablet faces several challenges that may limit widespread adoption.

Symtuza: FDA Approves New Fixed-Dose Combination for Treatment of HIV Img
News

Symtuza: FDA Approves New Fixed-Dose Combination for Treatment of HIV

On July 17, 2018 the U.S. Food and Drug Administration approved Symtuza, a four-drug combination indicated as a complete regimen for the treatment of HIV-1 infection in adults.